Top

BY Ron Gilmore

Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November by the Food and Drug Administration (FDA) for treatment of acute myeloid leukemia (AML) in patients not eligible for intensive chemotherapy.

Glasdegib, a hedgehog pathway inhibitor developed by Pfizer Inc., was approved for treatment following studies led by Jorge Cortes, M.D., professor...

acute myeloid leukemia blasts

BY Ron Gilmore

MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying pancreatic...

BY Ron Gilmore

Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according...

BY Ron Gilmore

Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) have published guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. These guidelines outline...

BY Ron Gilmore

A drug discovered and advanced by MD Anderson’s Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits...

BY Ron Gilmore

Triple-negative breast cancer (TNBC) is an aggressive form of the disease that doesn’t rely on the hormones estrogen and progesterone or the...

BY Ron Gilmore

The American Association for Cancer Research (AACR) has selected Isaiah J. Fidler, D.V.M., Ph.D., professor of Cancer Biology, as recipient...

BY Ron Gilmore

MD Anderson was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30% of the $73.5...

BY Ron Gilmore

Cell-based immunotherapies such as chimeric antigen receptors (CAR T), T-cell receptor (TCR) engineered T cells, tumor-infiltrating lymphocytes...

BY Ron Gilmore

Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone disease that accounts for one-fourth of all breast cancers, could...